Podemos Decides
This weekend’s Podemos congress will see the party make existential choices about its future.
21058 Article(s) by: Elizabeth Mahony
Remembering Red Vienna
Though tragically snuffed out by the rise of fascism, Red Vienna was an island of socialist organizing and workers’ power worth commemorating.
Being Anti-Trump Isn’t Enough
Silvio Berlusconi’s tenure reminds us that the Left needs to attack the neoliberal center, not just the populist right.
From Margins to Mainstream
The making of the modern Republican Party.
How the Donald Came to Rule
A radical middle-class insurgency has stormed the Republican Party.
The Trump Way
What kind of economic agenda does Trump have in store for workers?
False Answers
The Clinton establishment has every interest in obscuring why they really lost in November.
The Glory Days Are Over
Trump’s victory signals a deep crisis of neoliberalism.
Now What?
We must organize around ideas that give people something to fight for, not just something to fight against.
Results and Prospects: Q4 2016
With Trump in office, we need resistance, but also a credible alternative.
No Money, Mo’ Problems
We didn’t predict Trump, but we’re bound to get things right soon.
Discover the Networks
The new GOP is fueled by some old think tanks.
Coulterland
Buying these books really messed up our Amazon recommendation algorithm.
What Social Democracy Delivers
Ted Cruz is wrong. Workers in more social-democratic countries are richer and freer than in the US.
The Roots of Terrorism
US atrocities at home and abroad foster support for terrorist groups.
The Housing Crisis Is Not Inevitable
New York City can’t tackle its housing crisis without taking on real estate speculation.
Here We Go Again
The South Korea Olympics will kick off one year today. Will they face the same popular resistance as Rio?
Revolution Without Compromise
Before Marx, there was Auguste Blanqui.
Why We Counter-Protest
Ignoring the anti-abortion right has not made it go away.
Pharmageddon
The Left should push rising popular outrage at drug companies’ extortionate prices to its tipping point.